Literature DB >> 1642287

An unusually high prevalence of ocular toxoplasmosis in southern Brazil.

P D Glasner1, C Silveira, D Kruszon-Moran, M C Martins, M Burnier Júnior, S Silveira, M E Camargo, R B Nussenblatt, R A Kaslow, R Belfort Júnior.   

Abstract

Because of the frequency of ocular toxoplasmosis and its occurrence in multiple siblings in southern Brazil, a population-based household survey was performed to better understand the epidemiologic characteristics of the disease in this region. Of 1,042 individuals examined, 184 (17.7%) were deemed to have ocular toxoplasmosis on the basis of conservative assessment of ophthalmic findings. Of those with ocular toxoplasmosis, 183 (99.5%) had specific IgG antibodies, compared with only 140 of 181 age-matched control subjects (77.4%; P less than .001). The prevalence of ocular toxoplasmosis was 0.9% in 1- to 8-year-olds, 4.3% in 9- to 12-year-olds, 14.3% in 13- to 16-year-olds, and 21.3% (95% confidence interval, 18.6% to 24.2%) in all individuals 13 years or older. The prevalence of ocular toxoplasmosis in this population was more than 30 times higher than previous estimates for the same condition elsewhere. The low prevalence in the young children we studied supplements previous data suggesting that, in this population, ocular toxoplasmosis is a sequela of postnatal rather than congenital infection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1642287     DOI: 10.1016/s0002-9394(14)73976-5

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  87 in total

1.  Is ocular toxoplasmosis caused by prenatal or postnatal infection?

Authors:  R E Gilbert; M R Stanford
Journal:  Br J Ophthalmol       Date:  2000-02       Impact factor: 4.638

2.  Reliability of expert interpretation of retinal photographs for the diagnosis of toxoplasma retinochoroiditis.

Authors:  M R Stanford; L Gras; A Wade; R E Gilbert
Journal:  Br J Ophthalmol       Date:  2002-06       Impact factor: 4.638

3.  Severe acquired toxoplasmosis in immunocompetent adult patients in French Guiana.

Authors:  B Carme; F Bissuel; D Ajzenberg; R Bouyne; C Aznar; M Demar; S Bichat; D Louvel; A M Bourbigot; C Peneau; P Neron; M L Dardé
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

4.  Acquired ocular toxoplasmosis in pregnancy.

Authors:  M Ramchandani; J B Weaver; D H M Joynson; P I Murray
Journal:  Br J Ophthalmol       Date:  2002-08       Impact factor: 4.638

5.  CXCL10 is required to maintain T-cell populations and to control parasite replication during chronic ocular toxoplasmosis.

Authors:  Kazumi Norose; Akitoshi Kikumura; Andrew D Luster; Christopher A Hunter; Tajie H Harris
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-01-21       Impact factor: 4.799

Review 6.  Sexual recombination punctuated by outbreaks and clonal expansions predicts Toxoplasma gondii population genetics.

Authors:  Michael E Grigg; Natarajan Sundar
Journal:  Int J Parasitol       Date:  2009-02-13       Impact factor: 3.981

7.  Overlapping Spectrum of Retinochoroidal Scarring in Congenital Zika Virus and Toxoplasmosis Infections.

Authors:  Irena Tsui; Luiza M Neves; Kristina Adachi; Stephanie L Gaw; Jose Paulo Pereira; Patricia Brasil; Karin Nielsen-Saines; Maria Elisabeth Lopes Moreira; Andrea A Zin
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2019-12-01       Impact factor: 1.300

8.  Genetic diversity of Toxoplasma gondii isolates from chickens from Brazil.

Authors:  J P Dubey; G V Velmurugan; A Chockalingam; H F J Pena; L Nunes de Oliveira; C A Leifer; S M Gennari; L M G Bahia Oliveira; C Su
Journal:  Vet Parasitol       Date:  2008-08-05       Impact factor: 2.738

9.  HLA typing in congenital toxoplasmosis.

Authors:  C Meenken; A Rothova; L P de Waal; A R van der Horst; B J Mesman; A Kijlstra
Journal:  Br J Ophthalmol       Date:  1995-05       Impact factor: 4.638

10.  Anti-retinal autoantibodies in experimental ocular and systemic toxoplasmosis.

Authors:  Justus G Garweg; Yvonne de Kozak; Brigitte Goldenberg; Matthias Boehnke
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-12-03       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.